Cure My Disease

Don't miss your cure!

 Log in / Sign up

Psilocybin without the trip: scientists hunt for a microdose that skips hallucinations

NCT ID NCT07710027

Completed Knowledge-focused Sponsor: Diamond Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jul 17, 2026 · Last updated Jul 17, 2026

Summary

This study tests very low, single doses of psilocybin—the active compound in magic mushrooms—in healthy adults to find a dose that is safe and does not cause psychedelic effects like hallucinations or altered consciousness. Participants receive either a low dose of psilocybin (ranging from 0.5 mg up to 5 mg) or a placebo, and are monitored in a clinic for 2 nights. The goal is to identify a threshold dose below the level that triggers psychoactive experiences, which could be used in future research to explore potential benefits without the 'trip.'

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
psilocybin (low dose) or placebo
What this could lead to
If successful, this could identify a dose of psilocybin that is safe and non-psychedelic, potentially opening the door to studying its effects without the hallucinogenic experience.
What could go wrong
This is an early-phase, small study in healthy volunteers, so results may not apply to patients. Even if a non-psychedelic dose is found, it may not have any therapeutic benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY CONTROLS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

anxiety disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY CONTROLS

Contacts and locations

Locations

  • BioPharma Services Inc.

    Toronto, Ontario, M9L 3A2, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.